



8-27-04

JFW 1644

Attorney Docket No. 9250-5CTIP4XX

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: Fischer et al.

Serial No.: 10/019,087

Filed: December 19, 2001

For: METHOD FOR DETECTING A LIPOPROTEIN-ACUTE PHASE PROTEIN COMPLEX
AND PREDICTING AN INCREASED RISK OF SYSTEM FAILURE OR MORTALITY

Confirmation No. 3082

Group Art Unit: 1644

Examiner: P. Huynh

August 26, 2004

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97)

Sir:

Attached is a list of documents on form PTO-1449, along with the copies of each document cited therein, except as identified below.

Certain items were previously filed in the above-identified application. For the Examiner's convenience, the attached PTO-1449 lists these references already of record, and Applicants have attempted to identify such references by drawing a line therethrough. The Examiner is requested to verify that such documents were already listed on a PTO-1449 or PTO-892 to ensure that Applicants have not made any mistakes.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP.

In accordance with the requirements of 37 C.F.R. § 1.97(c)(2), a check for the \$180.00 fee specified in 37 C.F.R. § 1.17(p) is enclosed. This amount is believed to be correct. However, the Commissioner is authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

08/27/2004 SSANDARA 00000009 10019087

01 FC:1806

180.00 OP

Respectfully submitted,

Shawna Cannon Lemon
Registration No. 53,888

Customer Number 20792

Myers Bigel Sibley & Sajovec, P.A.
P.O. Box 37428, Raleigh, NC 27627
919-854-1400
919-854-1401 (Fax)

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV 472533711 US

Date of Deposit: August 26, 2004

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: Mail Stop Amendments, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan E. Freedman

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-5CTIP4XX

Serial No.
10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001

Group: 1644

U. S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	1.	3,307,392	03/07/67	Owen et al.	73	64.1	
	2.	3,458,287	07/29/69	Gross et al.	23	230	
	3.	3,658,480	04/25/72	Kane et al.	23	230 B	
	4.	4,040,788	8/9/77	Simons et al.	436	34	
	5.	4,047,890	09/13/77	Eichelberger et al.	23	230 B	
	6.	4,199,748	04/22/80	Bacus	340	146.3 CA	
	7.	4,217,107	08/12/80	Saito et al.	23	230 B	
	8.	4,279,616	07/21/81	Saito et al.	23	230 B	
	9.	4,289,498	09/15/81	Baughman et al.	23	230 B	
	10.	4,766,083	08/23/88	Miyashita et al.	436	517	
	11.	4,782,014	11/01/88	Serban et al.	435	7	
	12.	4,902,630	02/20/90	Bennett et al.	436	546	
	13.	4,965,725	10/23/90	Rutenberg	364	413.1	
	14.	4,998,535	03/12/91	Selker et al.	128	696	
	15.	5,003,065	03/26/91	Merritt et al.	540	469	
	16.	5,055,412	10/8/91	Proksch	436	69	
	17.	5,156,974	10/20/92	Grossman et al.	436	69	
	18.	5,169,786	12/08/92	Carroll et al.	436	69	
	19.	5,218,529	06/08/93	Meyer et al.	364	413.01	
	20.	5,221,628	06/22/93	Anderson et al.	436	5074	
	21.	5,358,852	10/25/94	Wu	435	7.94	
	22.	5,388,164	02/07/95	Yonekawa et al.	382	6	
	23.	5,473,551	12/05/95	Sato et al.	364	496	
	24.	5,473,732	12/05/95	Chang	395	77	
	25.	5,500,345	03/19/96	See et al.	435	7.1	
	26.	5,506,146	04/09/96	Josef	436	69	
	27.	5,525,477	6/96	Hassouna	436	69	

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office**
**Attorney Docket Number
9250-5CTIP4XX**
**Serial No.
10/019,087**
LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.
Filing Date: December 19, 2001
Group: 1644

	28.	5,526,111	6/96	Collins et al.	73	64.43	
	29.	5,553,616	09/10/96	Ham et al.	128	633	
	30.	5,563,983	10/08/96	Nozaki et al.	395	23	
	31.	5,567,596	10/96	Diamond et al.	435	13	
	32.	5,591,403	01/07/97	Gavin et al.	422	73	
	33.	5,593,897	01/14/97	Potempa et al.	436	507	
	34.	5,646,046	07/08/97	Fischer et al.	436	49	
	35.	5,670,329	09/23/97	Oberhardt	435	13	
	36.	5,705,395	01/98	Griffin et al.	436	69	
	37.	5,708,591	01/13/98	Givens et al.	364	497	
	38.	5,715,821	02/10/98	Faupel	1286	653.1	
	39.	5,716,795	02/10/98	Matschiner	435	13	
	40.	5,834,223	11/10/98	Griffin et al.	435	13	
	41.	5,856,114	01/05/99	Mann et al.	436	13	
	42.	5,862,304	01/19/99	Ravdin et al.	395	22	
	43.	5,981,285	11/99	Carroll et al.	702	23	
	44.	6,010,911	01/00	Baugh et al.	422	73	
	45.	6,040,147	03/21/00	Ridker et al.	435	7.24	
	46.	6,101,449	8/8/00	Givens et al.	702	22	
	47.	6,156,530	12/5/00	Rang.nby	435	40.5	
	48.	6,269,313	7/01	Givens et al.	702	22	
	49.	6,321,164	11/20/01	Braun et al.	702	22	

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation Yes No
	50.	EP 818 680	01/14/98	EP	G01N	33/546	
	51.	EP 841 566	05/13/98	EP	G01N	33/96	
	52.	EP 0 115 459	08/08/84	Europe	G01N	33/68	
	53.	EP 0 434 377	06/26/91	Europe	G01N	33/86	
	54.	EP 0 525 273	02/03/93	Europe	G01N	33/49	

EXAMINER
***EXAMINER**
DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office
Attorney Docket Number
 9250-5CTIP4XX

Serial No.
 10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001

Group: 1644

	55.	FR 2364 453	09/08/76	France - Abstract	G01N	33/16	
	56.	DE 2635081	02/09/78	Germany - Abstract	G01N	33/16	
	57.	DE 3502 878	01/29/85	Germany - Abstract	C12Q	01/56	
	58.	GB 2005014	04/11/79	Great Britain	G01N	33/16	
	59.	JP 59-203959	11/19/84	Japan - Abstract	G01N	33/86	
	60.	JP 60-114768	06/21/85	Japan - Abstract	G01N	35/02	
	61.	JP 61-272655	12/02/86	Japan - Abstract	G01N	33/49	
	62.	JP 05-180835	12/27/91	Japan - Abstract	G01N	33/53	
	63.	JP 06-027115	07/10/92	Japan - Abstract	G01N	33/86	
	64.	JP 04-254760	09/10/92	Japan - Abstract	G01N	33/53	
	65.	JP 06-249855	09/09/94	Japan - Abstract	G01N	33/86	
	66.	JP 10-104239	09/26/96	Japan - Abstract	G01N	33/86	
	67.	RU 2012877	04/01/91	Russia - Abstract	G01N	33/48	
	68.	RU 2061953	06/10/96	Russia - Abstract	G01N	33/86	
	69.	RU 2070327	12/10/96	Russia - Abstract	G01N	33/50	
	70.	SU 590665	02/11/76	SU - Abstract	G01N	33/16	
	71.	SU 1076086	02/29/84	SU - Abstract	A61B	5/14	
	72.	SU 1691741	08/25/89	SU - Abstract	G01N	33/48	
	73.	SU 1777089	06/08/90	SU - Abstract	G01N	33/86	
	74.	WO 86/06840	11/20/86	WIPO	G01N	33/86	
	75.	WO 89/09628	10/19/89	WIPO			
	76.	WO 91/00872	01/24/91	WIPO	C07K	15/28	
	77.	WO 91/01383	02/07/91	WIPO	C12Q	1/56	
	78.	WO 91/01497	02/07/91	WIPO	G01N	31/00	
	79.	WO 91/02812	03/07/91	WIPO	C12Q	1/56	
	80.	WO 91/05874	05/02/91	WIPO	C12Q	1/00	
	81.	WO 91/08460	06/13/91	WIPO	G01N	21/00	
	82.	WO 91/16453	10/31/91	WIPO	C12Q	1/56	
	83.	WO 93/09438	05/13/93	WIPO	G01N	33/68	
	84.	WO 93/24530	12/09/93	WIPO	C07K	15/06	
	85.	WO 94/07145	03/31/94	WIPO	G01N	33/86	

 EXAMINER
 *EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-5CTIP4XX

Serial No.
10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001

Group: 1644

	86.	WO 94/11714	05/26/94	WIPO	G01J	3/02	
	87.	WO 94/16095	07/21/94	WIPO	C12Q	1/00	
	88.	WO 95/05590	02/23/95	WIPO	G01N	1/28	
	89.	WO 95/08121	03/23/95	WIPO	G01N	33/86	
	90.	WO 96/42018	09/06/95	WIPO	G01N	33/86	
	91.	WO 95/30154	11/09/95	WIPO	G01N	33/86	
	92.	WO 96/06624	03/07/96	WIPO	A61K	35/16	
	93.	WO 96/14581	05/17/96	WIPO	G01N	33/86	
	94.	WO 96/21740	07/18/96	WIPO	C12Q	1/56	
	95.	WO 96/41291	12/19/96	WIPO	G06F	19/00	
	96.	WO 97/04317	02/06/97	WIPO	G01N	33/68	
	97.	WO 97/20066	06/05/97	WIPO	C12Q	1/56	
	98.	WO 97/34698	09/25/97	WIPO	B01L	3/00	
	99.	WO 98/09628	03/12/98	WIPO	A61K	31/495	
	100.	WO 99/34208	7/8/99	WIPO			
	101.	WO 99/47699	9/23/99	WIPO			
	102.	WO 93/07491	04/15/93	WIPO - Abstract	G01N	33/68	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	103.	<i>3 x 15 Test Kit for Detection of Plasma Protein C Activity Using a Clotting End-Point</i> , Product # ACC-45, American Diagnostica Inc., 1-2 (Feb. 1989).
	104.	Aillaud et al., <i>New Direct Assay of Free Protein S. Antigen Applied to Diagnosis of Protein S. Deficiency</i> , Thrombosis and Haemostasis, Vol. 75, No. 2, 1996, pp. 283-285.
	105.	Artherotech, <i>VAP/CAD Lipoprotein Risk Assessment Test and Sample of VAP Profile</i> , http://www.arterotech.com/risk_assessment.html
	106.	Astion, et al., <i>Overtraining in neural networks that interpret clinical data</i> , <i>Clin.Chem.</i> , 39(9):1998-2004 (1993).
	107.	Astion, et al., <i>The application of backpropagation neural networks to problems in pathology and laboratory medicine</i> , <i>Arch. Pathol. Lab. Med.</i> , 116:995-1001 (Oct. 1992).
	108.	Baum and Haussler, <i>What size net gives valid generalization?</i> , <i>Neural Computation</i> , pg 81-89 (Jan. 1989)
	109.	Baumann et al., "Simulation of the extrinsic pathway of the plasmatic clotting system," <i>Haemostasis</i> , 21:329-337 (1991).
	110.	Baumann, et al., <i>Computerized analysis of the in vitro activation of the plasmatic clotting system</i> , <i>Haemostasis</i> , 19:309-321 (1989).

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-SCTIP4XX

Serial No.
10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001

Group: 1644

111.	Bluestein and Archer, <i>The sensitivity, specificity and predictive value of diagnostic information: a guide for clinicians</i> , <u>Nurse Practitioner</u> , 16(7):39-45 (July 1991).
112.	Boone et al., <i>Neural networks in radiologic diagnosis</i> , <u>Investigative Radiology</u> , 25(9):1013-1023 (Sept. 1990).
113.	Brandt, et al., <i>Effect of lupus anticoagulants on the activated partial thromboplastin time. Results of the College of American Pathologists survey program</i> , <u>Arch.Pathol.Lab Med.</u> , 115:109-114 (Feb. 1991).
114.	Braun et al., <i>Examination of prothrombin time (PT) and activated partial thromboplastin time (APTT) optical clot profiles using an automated thrombosis-hemostasis</i> , <u>Coagulation Methods Instrumentation and Quality Control</u> , pg 1236, Abstract #1286 (1995).
115.	Braun, et al., <i>Properties of optical data from activated partial thromboplastin time and prothrombin time assays</i> , <u>Thromb.Haemost.</u> , 78:1079-1087 (1997).
116.	Cabana, et al., <i>Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins</i>, <u>J.Lipid Res.</u>, 30:39-49 (1989).
117.	Cabana, et al., <i>Inflammation induced changes in rabbit CRP and plasma lipoproteins</i>, <u>J.Immunol.</u>, 130(4):1736-1742 (April 1983).
118.	Cabana, et al., <i>Interaction of very low density lipoproteins (VLDL) with rabbit C-reactive protein</i>, <u>J.Immunol.</u>, 128(5):2342-2348 (May 1982).
119.	Canivet, et al., <i>Postoperative changes in lipid profile: their relations with inflammatory markers and endocrine mediators</i>, <u>Acta Anaesthesiol.Belg.</u>, 40(4):263-268 (1989).
120.	Carrol, et al., <i>Ortho Educational Monograph, The Clot Signature and New Aspects in Coagulation Testing</i> , Ortho Diagnostic Systems, Inc., pg. 1-20 (1989).
121.	Christner and Mortensen, <i>Specificity of the binding interaction between human serum amyloid P-component and immobilized human C-reactive protein</i>, <u>J.Biol.Chem.</u>, 269(13):9760-9766 (April 1994).
122.	Dassen, et al., <i>Self-learning neural networks in electrocardiography</i> , <u>J.Electrocardiol.</u> , 23 Suppl:200-202 (1990).
123.	de Beer, et al., <i>Low density lipoprotein and very low density lipoprotein are selectively bound by aggregated C-reactive protein</i>, <u>J.Exp.Med.</u>, 156:230-242 (July 1982).
124.	Dennis et al., <i>Utility of prothrombin time waveform analysis in the routine clinical setting</i>, <u>Abstract Instruction and Submission Form</u>, (Sept. 1999).
125.	Downey et al., <i>Early Identification and Prognostic Implications in Disseminated Intravascular Coagulation through Transmittance Waveform Analysis</i> , <u>Thromb. Haemost</u> 1998; 80: 65-9.
126.	Downey et al., <i>Novel and diagnostically applicable information from optical waveform analysis of blood coagulation in disseminated intravascular coagulation</i>, <u>Br.J.Haematol.</u>, 98:68-73 (1997).
127.	Downey et al., <i>The robustness and reproducibility of APTT waveform analysis in relation to reagent and batch variation</i>, <u>abstract only</u>.
128.	Downey et al., <i>Transmittance waveforms—adjunctive information from automated coagulometers</i>, <u>Int.J.Hematol.</u>, 64 Suppl:S160, Abstract #619, (Aug. 1996).
129.	Eitoku et al., "Studies on the Serum Amyloid A (SAA): Part 2 Latex Agglutination Nephelometric

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-5CTIP4XX

Serial No.
10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001

Group: 1644

		Immunoassay System for Quantitation of SAA in Human Serum and its Clinical Values," <i>Physico Chem. Biol.</i> , 37: 19-23 (Feb. 1993).
	130.	Engler, R., [<i>Acute phase proteins in inflammation</i>], <i>C.R. Seances Soc. Biol. Fil.</i> , 189(4):563-578 (1995).
	131.	Furlong, et al., <i>Neural network analysis of serial cardiac enzyme data. A clinical application of artificial machine intelligence</i> , <i>Am.J.Clin.Pathol.</i> , 96(1):134-141 (July 1991).
	132.	Gewurz, et al., <i>C-reactive protein and the acute phase response</i> , <i>Adv. Intern. Med.</i> , 27:345-372 (1982).
	133.	Givens and Braun, <i>Classification of factor deficiencies from coagulation assays using neural networks</i> , <i>Int.J.Med.Inf.</i> , 46:129-143 (1997).
	134.	Givens et al., <i>Interpretation of clot formation parameters from APTT and PT assays using neural networks</i> , <i>Clin.Chem.</i> , 42(6):S192, Abstract #399 (1996).
	135.	Givens, et al., <i>Predicting the presence of plasma heparin using neural networks to analyze coagulation screening assay optical profiles</i> , <i>Comput.Biol.Med.</i> , 26(6):463-476 (1996).
	136.	Givens, T.B., <i>Clot signatures</i> , <i>Clin.Hemostasis Rev.</i> , pg 11-12 (Aug. 1997).
	137.	Harris et al., <i>Reactivity of serum amyloid P component with C-reactive protein and IgM</i> , <i>Clin.Res.</i> , 37, Abstract #614A (1989).
	138.	Heuck and Baumann, <i>Kinetic analysis of the clotting system in the presence of heparin and depolymerized heparin</i> , <i>Haemostasis</i> , 21:10-18 (1991).
	139.	Hoffman and Callahan, <i>The Coag-A-Mate RA4 Fibrinogen Assay</i> , <i>Interface</i> (Organon Teknika), pg 3-7 (1990).
	140.	Hulman and Fuller, <i>Comparison of fat agglutination slide test and latex test for C-reactive protein</i> , <i>Clin.Chim.Acta</i> , 165:89-93 (5-29-1987).
	141.	Hulman, et al., <i>Agglutination of intralipid by sera of acutely ill patients</i> , <i>Lancet</i> , 2:1426-1427 (Dec. 1982).
	142.	Hulman, G., <i>The pathogenesis of fat embolism</i> , <i>J.Pathol.</i> , 176:3-9 (1995).
	143.	Husebekk, et al., <i>High-density lipoprotein has different binding capacity for different apoproteins. The amyloidogenic apoproteins are easier to displace from high-density lipoprotein</i> , <i>Scand.J.Immunol.</i> , 28:653-658 (1988).
	144.	International Preliminary Examination Report for PCT/US01/18611.
	145.	International Search Report, International Application No. PCT/US00/21022, Dated 22 January 2001.
	146.	Khanin and Semenov, <i>A mathematical model of the kinetics of blood coagulation</i> , <i>J.Theor.Biol.</i> , 136:127-134 (Jan. 1989).
	147.	<i>Koagulab 16-S Plus Graphics, Koagulab 32-S Coagulation System, Graphics Binder</i> , 2,3,5,6,8-12, 14-17,19-21,23.
	148.	Lagrand, et al., <i>C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?</i> , <i>Circulation</i> , 100:96-102 (July 1999).

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-5CTIP4XX

Serial No.
10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001


Group: 1644

149.	Lindh, et al., Agglutinate formation in serum samples mixed with intravenous fat emulsions, Crit Care Med., 13(3):151-154 (March 1985).
150.	Malle, et al., Serum amyloid A (SAA): an acute phase protein and apolipoprotein, Atherosclerosis, 102:131-146 (1993).
151.	Maury, C.P.J. "Clinical Usefulness of Serum Amyloid A and C-reactive Protein Measurements in Inflammatory Disorders a Comparative Study," Marker Proteins in Inflammation Proceedings, vol. 3, Symposium, Lyon, France, June 1985 (abstract only).
152.	McCarty, M., Historical perspective on C-reactive protein, Ann.N.Y.Acad.Sci., 389:1-10 (1982).
153.	McDonald, et al., A monoclonal antibody sandwich immunoassay for serum amyloid A (SAA) protein, J.Immunol.Methods, 144:149-155 (11-22-1991).
154.	Ortho Factor VIII: C Deficient Plasma, Ortho Diagnostic Systems, Inc., pp. 1-2 (September 1998)
155.	Package insert for Ortho Brain Thromboplastic Reagent, Ortho Diagnostic System, Inc., pg. 1-7 (Oct. 1985).
156.	Pattichis, et al., Efficient training of neural network models in classification of electromyographic data, Med.Biol.Eng Comput., 33(3):499-503 (May 1995).
157.	Pepys, et al., C-reactive protein: binding to lipids and lipoproteins, Int.Rev.Exp.Pathol., 27:83-111 (1985).
158.	Pohl, et al., The quick machine--a mathematical model for the extrinsic activation of coagulation, Haemostasis, 24:325-337 (1994).
159.	Preciado-Pratt et al. Serum Amyloid A Complexed with Extracellular Matrix Induces the Secretion of Tumor Necrosis Factor-alpha by Human T-lymphocytes, Letters in Peptide Science, vol. 5, (1998), no. 5-6, pl 349-55 (abstract only).
160.	Richter, et al., The fat emulsion agglutination test: a reliable and cost effective alternative to the latex agglutination test for rapid bedside CRP measurement, Clin.Chim.Acta, 261:141-148 (May 1997).
161.	Robin et al., Prognostic value of waveform analysis in the intensive care setting, Intensive Care Med., 25(Suppl 1):S63 (1999).
162.	Rowe, et al., Agglutination of intravenous lipid emulsion ('Intralipid') and plasma lipoproteins by C-reactive protein, Clin.Exp.Immunol., 66:241-247 (1986).
163.	Rowe, et al., Circulating human C-reactive protein binds very low density lipoproteins, Clin.Exp.Immunol., 58:237-244 (1984).
164.	Rowe, et al., In vivo turnover studies of C-reactive protein and lipoproteins in the rabbit, Clin.Exp.Immunol., 58:245-252 (1984).
165.	Rowe, et al., Rabbit and rat C-reactive proteins bind apolipoprotein B-containing lipoproteins, J.Exp.Med., 159:604-616 (Feb. 1984).
166.	Rybarska et al. "The Detection of Specific Acute Phase Serum Protein Complexes and Immune Complexes by Congo Red Binding," Journal of Physiology and Pharmacology, 1995, vol. 46 (2), pp. 221-31 (abstract only).
167.	Sabbatini, R.M.E., Neural networks for classification and pattern recognition of biological samples, Conf.of the Engineering in Medicine and Biology Society (IEEE, New York, U.S.)

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449 U.S. Department of Commerce Patent and Trademark Office		Attorney Docket Number 9250-5CTIP4XX	Serial No. 10/019,087
LIST OF DOCUMENTS CITED BY APPLICANT (Use several sheets if necessary)		Applicants: Fischer et al.	
		Filing Date: December 19, 2001	Group: 1644
		15:265-266 (Oct. 1983).	
	168.	Sammalkorpi, et al., Lipoproteins and acute phase response during acute infection. Interrelationships between C reactive protein and serum amyloid A protein and lipoproteins, Ann.Med., 22:397-401 (1990).	
	169.	Schwalbe, et al., Association of rat C reactive protein and other pentraxins with rat lipoproteins containing apolipoproteins E and A1, Biochemistry, 34(33):10432-10439 (Aug. 1995).	
	170.	Schweiger, et al., Evaluation of laboratory data by conventional statistics and by three types of neural networks, Clin.Chem., 39(9):1966-1971 (1993).	
	171.	Simmons, A. Ethanol gel solubility test, In: Technical Hematology, 3rd Edition, J.B. Lippincott Company, Philadelphia, PA, pg. 334-335 (1980).	
	172.	Stewart, et al., Sensitive and rapid measurement of C reactive protein (CRP) by lipid agglutination, J.Clin.Pathol., 40:585-588 (1987).	
	173.	Supplementary European Search Report, European Application No. 00953788.7, 05/19/2003.	
	174.	Supplementary European Search Report, European Application No. 00953788.7, 06/05/2003.	
	175.	Swanson, et al., Human serum amyloid P component (SAP) selectively binds to immobilized or bound forms of C reactive protein (CRP), Biochim.Biophys.Acta, 1160:309-316 (12-28-1992).	
	176.	Sweeney et al., Abnormal clot signatures in hereditary bleeding disorders, <u>Blood</u> , 74 Suppl 1(7):395, Abstract #1509 (Nov. 1989).	
	177.	Sweeney et al., Abnormal clot signatures in hereditary bleeding disorders, <u>The American Society of Hematology Abstract Reproduction Form</u> (1989).	
	178.	Sweeney et al., Kinetic clot parameters in gynecological tumors, <u>Blood</u> , 76 Suppl 1(10):439a, Abstract #1745-(Nov. 1990).	
	179.	Swets, J. A., Measuring the accuracy of diagnostic systems, <u>Science</u> , 240:1285-1293 (June 1988).	
	180.	Talstad, I., Which coagulation factors interfere with the one-stage prothrombin time?, <u>Haemostasis</u> , 23:19-25 (1993).	
	181.	Toh and Downey, A previously unrecognized mechanism that is calcium dependent and thrombin-independent characterizes the pre-DIC state, The American Society of Hematology, 1999 Submission Form, Abstract #450426 (1999).	
	182.	Toh and Downey, The mechanism underlying the atypical clot waveform profile of DIC is thrombin-independent but calcium dependent, European Haematology Association, Abstract Form (June 2000).	
	183.	Toh et al., APTT Waveform analysis: predicting mortality in the critical care setting using the light transmittance level at 18 seconds, XVII Congress International Society for Thrombosis & Haemostasis, Abstract Submission Form, (Aug. 1999).	
	184.	Toh et al., Characterization of the novel calcium activation, thrombin suppression assay (CaTs) in the DIC of sepsis, abstract only.	
	185.	Toh et al., Impending clinical decompensation is characterized by the detection of a novel calcium-dependent and thrombin-independent pathway, 5th World Congress on Trauma, Shock, Inflammation and Sepsis—Pathophysiology, Immune Consequences and Therapy, Abstract	

EXAMINER
*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 U.S. Department of Commerce
Patent and Trademark Office

Attorney Docket Number
9250-5CTIP4XX

Serial No.
10/019,087

LIST OF DOCUMENTS CITED BY APPLICANT

(Use several sheets if necessary)

Applicants: Fischer et al.

Filing Date: December 19, 2001

Group: 1644

Submission Form, (Feb. 2000).

186. ~~Toh et al., Prospective detection of pre-disseminated intravascular coagulation (DIC) in a sepsis cohort by waveform analysis, XVII Congress International Society for Thrombosis & Haemostasis, Abstract Submission Form, (Aug. 1999).~~

187. ~~Toh et al., Waveform analysis of the prothrombin time (PT) assay also shows characteristic changes in disseminated intravascular coagulation, XVII Congress International Society for Thrombosis & Haemostasis, Abstract Submission Form, (Aug. 1999)~~

188. ~~Toh, C.H., Disseminated intravascular coagulation (DIC): Old problem, new hope, Clin.Hemostasis Rev., pg 18 (Jan. 1998).~~

189. Triplet, et al., Graphic monitoring of coagulation assays, American Clinical Laboratory, pg 1-5 (April 1989).

190. ~~Wilkins, et al., Rapid automated enzyme immunoassay of serum amyloid A, Clin.Chem., 40(7):1284-1290 (1994).~~

191. Zuckerman et al. "Comparison of thrombelastography with common coagulation tests," *Thromb Haemostas*, 46: 752-6 (1981).

192. Zweig and Campbell, Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine, Clin.Chem., 39(4):561-577 (1993).

EXAMINER

*EXAMINER

DATE CONSIDERED

Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.